Table 6B.
Secondary clinical outcomes by type of prism treatment initiated at enrollmenta
| Questionnaire | Enrollment | 10 weeks | 12 months | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||||||
| Correcting n = 10 | High relieving n = 12 | Low relieving n = 10 | Correcting n = 9 | High relieving n = 12 | Low relieving n = 9 | Correcting n = 10 | High relieving n = 8 | Low relieving n = 7 | |||||||
|
| |||||||||||||||
| DQb | 44 ± 22 | 42 ± 18 | 38 ± 18 | 13 ± 25 | −30 (−61 to 0) | 13 ± 22 | −28 (−44 to −13) | 10 ± 26 | −30 (−45 to −15) | 17 ± 26 | −27 (−47 to −6) | 20 ± 31 | −21 (−36 to −7) | 15 ± 26 | −24 (−50 to 2) |
| AS-20 | |||||||||||||||
| General Functionc | 67 ± 30 | 58 ± 27 | 68 ± 20 | 85 ± 18 | 16 (−8 to 41) | 83 ± 13 | 25 (9 to 41) | 83 ±20 | 14 (4 to 24) | 79 ± 29 | 11 (−3 to 26) | 75 ± 11 | 15 (−4 to 34) | 84 ± 17 | 17 (−9 to 43) |
| Reading Functionc | 75 ± 25 | 83 ± 16 | 80 ± 24 | 77 ± 24 | 1 (−15 to 17) | 84 ± 21 | 1 (−12 to 14) | 84 ± 25 | 7 (−7 to 20) | 86 ± 17 | 10 (−3 to 24) | 78 ± 23 | −5 (−28 to 18) | 90 ± 12 | 16 (−12 to 44) |
| Self-Perceptionc | 94 ± 12 | 86 ± 24 | 97 ± 6 | 96 ± 9 | 2 (−2 to 7) | 84 ± 17 | −2 (−14 to 11) | 95 ± 8 | −2 (−10 to 5) | 94 ± 8 | 0 (−8 to 9) | 90 ± 18 | 7 (−19 to 32) | 99 ± 2 | 3 (−2 to 9) |
| Interactionc | 94 ± 12 | 92 ± 12 | 100 ± 0 | 97 ± 9 | 3 (−3 to 10) | 90 ± 12 | −3 (−11 to 6) | 99 ± 2 | 0 (−2 to 1) | 98 ± 7 | 4 (−2 to 10) | 96 ± 5 | 1 (−6 to 9) | 100 ± 0 | 0 (0 to 1) |
CI, confidence interval; HRQOL, health-related quality of life; SD, standard deviation.
a
Scoring results shown as either mean ± SD or mean change from baseline (95% CI).
b
Diplopia Questionnaire (DQ) scores range from 0 to 100, with 0 being best (no diplopia) and 100 being worst (diplopia in all gazes all the time); improvement is thus reflected as negative change.
c
Adult Strabismus-20 questionnaire domain scores range from 0 to 100, with 0 being the worst HRQOL and 100 being the best HRQOL; improvement is thus reflected as positive change.